Table 1.
Study demographicsa
| Control (n = 66) | Patient (n = 84) | |
|---|---|---|
| Age | 38.2 ± 10.9 | 39.4 ± 10.6 |
| Male (%) | 71 | 81 |
| Socioeconomic status, parental* | 42.7 ± 14.5 | 36.0 ± 12.0 |
| Socioeconomic status, participant* | 44.0 ± 10.8 | 27.6 ± 15.1 |
| Chlorpromazine equivalents (Woods 2003) | — | 932 ± 1032 mg |
| Atypical (alone or combination) (%) | — | 90% |
| Illness duration | — | 15.9 ± 9.4 |
| PANSS total | — | 73.2 ± 14.9 |
| PANSS positive | — | 19.1 ± 6.2 |
| PANSS negative | — | 18.1 ± 4.7 |
| PANSS general | — | 36.0 ± 7.7 |
| MMN to FM tones (n) | 36 | 43 |
| MRI (n)b | 51 | 55 |
| Both MRI and MMN to FM tones (n) | 21 | 14 |
| MMN to non-FM (simple) tones (n) | 23 | 28 |
aParental socioeconomic status information was not available for 27 patients and 8 controls. Individual SES data were unavailable for 9 patients and one control. Chlorpromazine equivalents was unavailable for 3 patients. PANSS was unavailable on 21. Antipsychotic subtype was unavailable on 4 patients. PANSS, Positive and negative syndrome scale for schizophrenia.
bA total of 63% of controls and 63% of patients were scanned on the 3T, with the remainder on 1.5T.
*Significant difference on independent sample t test.